You are here: Industry Insights > Merck

News List

Additional Cohorts to Evaluate LNS8801 in Combination with KEYTRUDA(R) in Patients with Advanced Cancer americanpharmaceuticalreview
June 17, 2021
Linnaeus Therapeutics Inc. announced the expansion of its ongoing clinical collaboration with Merck to include multiple additional phase 2 cohorts.
Merck signs $1.2bn supply deal with US for antiviral molnupiravir pharmaceutical-technology
June 10, 2021
Merck (MSD) has signed an agreement, valued at about $1.2bn, with the US Government to supply its investigational oral antiviral candidate, molnupiravir (MK-4482) to treat mild to moderate Covid-19.
Merck completes spinoff of women’s health company Organon pharmaceutical-technology
June 07, 2021
Merck (MSD) has completed the spinoff of Organon to boost its focus on growth areas, realise higher revenue and earnings per share (EPS) growth rates.
Merck and Sanofi’s First and Only Six-in-One Pediatric Combination Vaccine Now Available in the US americanpharmaceuticalreview
June 04, 2021
VAXELIS™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine), developed as part of a U.S.-based partnership between Merck and Sanofi Pasteur is now available in the ...
Merck announces two million euros as support to India for Covid relief expresspharma
June 02, 2021
The aid is being utilised for procuring equipment of 250 oxygen concentrators, 100 ventilator units, and setting up oxygen generation plants in four hospitals.
Merck launches synthetic cholesterol product to meet high demand for lipids expresspharma
May 31, 2021
This neutral lipid, used in commercially marketed products, is more than 99 per cent pure; offers high batch-to-batch consistency and is scalable under commercial GMP.
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® in Combination With Chemotherapy as First-Line Treatment for Patients With Esophageal Cancer or GEJ Adenocarcinoma americanpharmaceuticalreview
May 25, 2021
Merck announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum- and ...
Merck Announces Positive Topline Results from Investigational 15-valent Pneumococcal Conjugate Vaccine americanpharmaceuticalreview
May 24, 2021
Merck has announced that V114, the company’s investigational 15-valent pneumococcal conjugate vaccine, met its primary immunogenicity and safety endpoints in two trials of the V114 Phase 3 pediatric clinical program.
BioMedX Extends Collaboration with Merck contractpharma
May 18, 2021
Merck will support up to six more research groups at the BioMed X Institute in Heidelberg within the next six years.
Preliminary NICE 'no' for Merck's Bavencio pharmatimes
May 07, 2021
The National Institute for Health and Care Excellence (NICE) has issued a preliminary rejection of NHS funds for use of Merck Serono's Bavencio (avelumab) as maintenance treatment of locally advanced or metastatic urothelial cancer.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page